Benzyl Bromide

Benzyl Bromide

SCHEMBL438870

BrCc1ccccc1.CN(C)C

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.78
ALDH1A1 P00352 2/20 0.78
TRPA1 O75762 1/20 0.78
AOC3 Q16853 3/20 0.48
TAAR1 Q96RJ0 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
TP53 P04637 1/20 0.46
CALM1 P0DP23 1/20 0.43
SLC6A2 P23975 2/20 0.41
SLC6A4 P31645 2/20 0.41
ADRA1A P35348 2/20 0.41
SLC6A3 Q01959 2/20 0.41
KCNH2 Q12809 2/20 0.41
CARM1 Q86X55 1/20 0.41
PRMT6 Q96LA8 1/20 0.41
PRMT8 Q9NR22 1/20 0.41
CHRM2 P08172 1/20 0.41
HTR1A P08908 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzyl Bromide SCHEMBL5964841 0.88
SCHEMBL20389321 0.88 TSHR (1.00) TSHRALDH1A1TRPA1TAAR1TDP1
Benzyl Bromide SCHEMBL1066 0.88
Benzyl Bromide SCHEMBL9000955 0.88 TSHR (1.00) TSHRALDH1A1TRPA1TAAR1TDP1
Benzyl Bromide SCHEMBL1331189 0.88
Benzyl Bromide SCHEMBL5757393 0.88 TSHR (1.00) TSHRALDH1A1TRPA1TAAR1TDP1
Benzyl Bromide SCHEMBL28230984 0.86 ALDH1A1 (0.82) TSHRALDH1A1TRPA1TAAR1TDP1
Benzyl Bromide SCHEMBL3764294 0.86 ALDH1A1 (0.82) TSHRALDH1A1TRPA1TAAR1TDP1
Benzyl Bromide SCHEMBL28763610 0.86 ALDH1A1 (0.82) TSHRALDH1A1TRPA1TDP1CES2
Benzyl Bromide SCHEMBL27727270 0.86 ALDH1A1 (0.82) TSHRALDH1A1TRPA1TAAR1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11717481-B2 Reduction of flake-like aggregation in nanoparticulate active agent compositions ALKERMES PHARMA IRELAND LIMITED (IE) 2023-08-08 US claimed
CN-113260637-B Modified diene (co) polymers, method for the production thereof and use thereof as flame retardants 公共型股份公司希布尔控股 2023-06-16 CN claimed
US-20220211626-A1 REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2022-07-07 US claimed
US-11253478-B2 Reduction of flake-like aggregation in nanoparticulate active agent compositions ALKERMES PHARMA IRELAND LIMITED (IE) 2022-02-22 US claimed
EP-3755148-A1 NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME RHNanoPharma (US) 2020-12-30 EP claimed
US-20200390737-A1 NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME RHNANOPHARMA (US) 2020-12-17 US claimed
WO-2020065541-A1 MICROEMULSIONS AND METHODS OF USE MOROCCANOIL ISRAEL, LTD. (IL) 2020-04-02 WO claimed
WO-2019165240-A1 NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME RHNANOPHARMA (US) 2019-08-29 WO claimed
CN-110036045-A The production method of polyacrylonitrile SABIC环球技术有限责任公司 2019-07-19 CN claimed
US-20180250229-A1 REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS ALKERMES PHARMA IRELAND LIMITED (IE) 2018-09-06 US claimed
WO-2003066021-A2 DRUG NANOPARTICLES WITH LYSOZYME SURFACE STABILISER ELAN PHARMA INTERNATIONAL, LTD. (IE) 2003-08-14 WO claimed
US-20030137067-A1 Compositions having a combination of immediate release and controlled release characteristics ELAN PHARMA INTERNATIONAL LTD. 2003-07-24 US claimed
US-20030095928-A1 Nanoparticulate insulin ELAN PHARMA INTERNATIONAL LIMITED 2003-05-22 US claimed
WO-2003030872-A2 COMPOSITIONS HAVING A COMBINATION OF PARTICLES FOR IMMEDIATE RELEASE AND FOR CONTROLLED RELEASE ELAN PHARMA INTERNATIONAL LTD. (IE) 2003-04-17 WO claimed
WO-2003024425-A1 NANOPARTICULATE INSULIN FORMULATIONS ELAN PHARMA INTERNATIONAL, LTD. (IE) 2003-03-27 WO claimed
EP-0553111-B1 THIN FILM COMPOSITE ULTRAFILTRATION MEMBRANE ALLIED SIGNAL INC (US) 1995-09-06 EP claimed
EP-0553111-A1 THIN FILM COMPOSITE ULTRAFILTRATION MEMBRANE. ALLIED SIGNAL INC (US) 1993-08-04 EP claimed
US-5145584-A Polymer anions and cations for membrane ALLIED-SIGNAL INC. (US) 1992-09-08 US claimed
WO-1992010280-A1 THIN FILM COMPOSITE ULTRAFILTRATION MEMBRANE ALLIED-SIGNAL INC. (US) 1992-06-25 WO claimed
US-5085775-A Casting solution of polyelectrolyte complex on microporous support; asymmetric; separation of low molecular weight solutes ALLIED-SIGNAL INC. (US) 1992-02-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390737-A1 NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME TUBAL3, TUBB6, TUBA1A TSHR 4295/4885ALDH1A1 316/4885TRPA1 4508/4885
US-20030137067-A1 Compositions having a combination of immediate release and controlled release characteristics NAPA, CD63, RPL36 TSHR 2057/4885ALDH1A1 2257/4885TRPA1 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.